GPCR240719P65000
- 16.00
- 0.000.00%
Structure Therapeutics Newsroom
Jefferies Maintains Structure Therapeutics(GPCR.US) With Buy Rating, Maintains Target Price $79
BMO Capital Maintains Structure Therapeutics(GPCR.US) With Buy Rating, Maintains Target Price $100
Pfizer's CEO announced the development of three new weight loss drugs, one of which is not a GLP-1 medication.
Pfizer's (PFE.US) CEO, Albert Bourla, said that the pharmaceutical company is testing three new weight loss drugs.
Goldman Sachs and Cantor Fitzgerald have a tacit agreement that the monopoly of "Norris" in the weight loss drug market is difficult to change.
Two top Wall Street analysts have reached a consensus, emphasizing that global weight loss drug market leaders "Novo" may continue to dominate the highly profitable weight loss drug market.
Lilly, Novo Nordisk to Dominate Weight Loss Therapy Market: SA Investing Summit
Obesity-Drug Developers Look at What's Next for a $100 Billion Market -- Barrons.com
Express News | Cantor Fitzgerald Reiterates Overweight on Structure Therapeutics, Maintains $65 Price Target
Could Structure Therapeutics Become the Next Novo Nordisk?
USA faces the most severe drug shortage in a decade, with low stock price drugs and weight loss drugs becoming "disaster zones".
Last year, the USA experienced the most serious drug shortage crisis in a decade.
JPMorgan to Wager on Weight-Loss Craze With $500 Million Fund
GLP-1 Obesity Drug Coverage Dropped by Blue Cross Michigan: Report
Structure Therapeutics (GPCR) Rallying on Obesity Drug Data
Structure Therapeutics Stock Could Rocket 87% Higher, According to 1 Wall Street Analyst. Is It Time to Buy?
Structure Therapeutics' Stock Is Soaring on the Promise of Its Wegovy Competitor, but Is It a Buy?
Press Release: Structure Therapeutics Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional American Depositary Shares
Structure Therapeutics Is Maintained at Outperform by BMO Capital
Structure Therapeutics Analyst Ratings
Express News | Structure Therapeutics Inc : BMO Raises Target Price to $100 From $83
Structure Therapeutics Vs. Viking Therapeutics: Which Weight-Loss Drug Stock Wins?
Structure Therapeutics Prices Upsized $476 Million Stock Offering